Search company, investor...
CellCentric company logo


Founded Year



Series F | Alive

Total Raised


About CellCentric

CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.

Headquarters Location

Chesterford Research Park Little Chesterford

Cambridge, England, CB10 1XL,

United Kingdom

+44 (0) 1799 531130

Missing: CellCentric's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CellCentric's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CellCentric

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CellCentric is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CellCentric Patents

CellCentric has filed 19 patents.

The 3 most popular patent topics include:

  • Fuel cells
  • Hydrogen technologies
  • Hydrogen economy
patents chart

Application Date

Grant Date


Related Topics




Fuel cells, Industrial gases, Sensors, Hydrogen technologies, Engine technology


Application Date


Grant Date



Related Topics

Fuel cells, Industrial gases, Sensors, Hydrogen technologies, Engine technology



Latest CellCentric News

Volvo Triples Electric Truck Dealer Network Since Last Year

May 5, 2023

56 More Locations on Track to Obtain EV Certification VTNA President Peter Voorhoeve outlines the truck maker’s sustainability strategy at ACT Expo in Anaheim, Calif. (Matt Pratt) ANAHEIM, Calif. — As Volvo Trucks continues to roll out battery-electric heavy-duty trucks to fleet customers across North America, the truck maker also is building its support network for those vehicles. During the past year, Volvo has tripled the number of dealers certified to sell and service its Volvo VNR Electric trucks, the company announced May 2 at the 2023 Advanced Clean Transportation Expo . As of May, the manufacturer’s EV dealer network had expanded to 39 locations, up from 12 a year earlier, with certified dealers located across 19 U.S. states and in three provinces of Canada. An additional 56 locations are in the process of obtaining EV certification, which will expand Volvo’s EV dealer presence to a total of 37 U.S. states and four Canadian provinces. "It gives us great pride to be leading the shift towards sustainable transportation"- Volvo President Peter Voorhoeve at #ACTExpo — Volvo Trucks North America (@VolvoTrucksNA) May 3, 2023 “Our dealer partners have invested in the zero-emission future with us because they understand the future is here today,” said Peter Voorhoeve, president of Volvo Trucks North America . “Battery-electric trucks are on the road and scaling — and we have the experience and expertise to guide fleets through successfully adopting the Volvo VNR Electric into their operations to make a real impact on decarbonization.” Volvo’s certified EV dealership program is designed to establish the sales and service network required to support electric truck deployments. Sales teams at these certified EV dealers are prepared to offer consulting to customers considering deploying the VNR Electric model in their fleet operations. These certified dealers also provide scheduled and preventive maintenance, towing and repairs, including servicing the vehicle’s energy storage and electromobility system. Image A fuel cell from the Cellcentric partnership showcased at ACT Expo in Anaheim, Calif. (Volvo Trucks North America) At ACT Expo, Volvo showcased a Volvo VNR Electric model built for warehousing and distribution provider Performance Team, a Maersk company. The truck is one of 126 VRN Electric models that Performance Team is deploying. Volvo’s exhibit also included hydrogen fuel cell technology developed by Cellcentric, a joint venture of Volvo and Daimler Truck, as well as an e-axle electric driveline concept. Also at the booth, Volvo Autonomous Solutions showed a VNL760 model equipped with the Aurora Driver , which remains in testing and development with the goal of enabling autonomous longhaul freight transportation.

CellCentric Frequently Asked Questions (FAQ)

  • When was CellCentric founded?

    CellCentric was founded in 2004.

  • Where is CellCentric's headquarters?

    CellCentric's headquarters is located at Chesterford Research Park, Cambridge.

  • What is CellCentric's latest funding round?

    CellCentric's latest funding round is Series F.

  • How much did CellCentric raise?

    CellCentric raised a total of $73.9M.

  • Who are the investors of CellCentric?

    Investors of CellCentric include Morningside Ventures, BrightEdge, Providence Investment, UK Innovation & Science Seed Fund, Innovate UK and 11 more.

  • Who are CellCentric's competitors?

    Competitors of CellCentric include Forma Therapeutics, EUCODIS Bioscience, Cognition Therapeutics, Prosarix, Proteostasis Therapeutics and 11 more.

Compare CellCentric to Competitors


Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Lead Therapeutics

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule pre-IND candidates against clinically validated therapeutic targets by leveraging the best of the US and China. Headquartered in the San Francisco Bay Area, LEAD Therapeutics is led by an experienced small molecule drug discovery team with proven track records in the pharmaceutical and biotech industries. The company plans to carry out the majority of its discovery research activities in China.


Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.nThe company seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.nThe company's antimicrobial expertise is now also being successfully applied to other areas as the company develop collaborative relationships with major healthcare companies.

InVasc Therapeutics

InVasc Therapeutics specializes in target-specific drug discovery and has developed a approach to drug discovery that uses molecular structures and an application-based platform that decreases the time and expense of current large-scale "mining"� discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.